中国临床药学杂志

目的评价西妥昔单抗联合化疗方案治疗晚期结直肠癌的疗效及不良反应。方法选择我院2007年1月-2010年6月单用或联合化疗使用西妥昔单抗治疗晚期或转移性结直肠癌患者35例,采用RF,cISr 1.1版实体肿瘤客观疗效评定标准进行临床疗效评价。并采用美国毒性反应评价标准(CIE 3.0)进行不良反应评价。结果共有31例纳入疗效评价。其中完全缓解l例,部分缓解9例,疾病稳定14例,疾病进展7例,有效率32.3%,疾病控制率75.O%;K-RAS基因野生型的患者有效率(40.0%)明显高于未检测组(18.2%)。33例发生了不良反应,发生率94.3%,主要为I～Ⅱ级(占74.1%)。结论西妥昔单抗联合放化疗方案治疗晚期结直肠癌可获得较高有效率,延长了疾病进展时间。

AIM To investigate the response and adverse drug reactions of cetuximab treatment combined with radio - and chemo- therapy in advanced colorectal cancer patients.METHODS From Jan.2007 to Jun.2010,clinical data of 35 patients with advanced or metastatic colorectal cancer treated by cetuximab singly or by cetuximab combined with chemotherapy were analyzed.The clinical curative effect and adverse drug reactions as well as the effective response rate of patients with wild-type K-RAS were studied.RESULTS There,was one patient reached complete response(CR),9 patients reached partial response(PR),14 patients were in stable condition(SC),and the 7 patients were disease progression (DP).The effective response rate was 32.3%,disease control rate(DCR) was 75.0%.The effective response rate(40.0%)of patients with wild-type K-RAS was better than untested group(18.2%).The adverse effect incidence rate was 94.3%,andⅠ-Ⅱgrade adverse drug reactions happened most frequently which accounted for 74.1%. CONCLUSION The effective response rate of cetuximab treatment combined with radio- and chemo- therapy in advanced colorectal cancer patients is pretty high,and the combination treatment which prolonged the time-to-progression (TIP) and is worthy of clinical application.